Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,067 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching.
Shimose S, Iwamoto H, Niizeki T, Tanaka M, Shirono T, Moriyama E, Noda Y, Nakano M, Suga H, Kuromatsu R, Torimura T, Koga H, Kawaguchi T. Shimose S, et al. Among authors: noda y. Int J Mol Sci. 2023 Sep 5;24(18):13715. doi: 10.3390/ijms241813715. Int J Mol Sci. 2023. PMID: 37762018 Free PMC article.
Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study.
Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Nakano M, et al. Among authors: noda y. Mol Clin Oncol. 2017 Dec;7(6):1013-1020. doi: 10.3892/mco.2017.1442. Epub 2017 Oct 4. Mol Clin Oncol. 2017. PMID: 29285366 Free PMC article.
Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching.
Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Kawaguchi A, Koga H, Yokokura Y, Torimura T. Shimose S, et al. Among authors: noda y. Hepatol Res. 2019 Aug;49(8):919-928. doi: 10.1111/hepr.13348. Epub 2019 May 13. Hepatol Res. 2019. PMID: 30969006
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study.
Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, Yamaguchi T, Kawaguchi T, Tanaka M, Noguchi K, Koga H, Torimura T. Shimose S, et al. Among authors: noda y. Cancers (Basel). 2020 Jul 11;12(7):1867. doi: 10.3390/cancers12071867. Cancers (Basel). 2020. PMID: 32664489 Free PMC article.
Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis.
Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Nakano M, et al. Among authors: noda y. Hepatol Commun. 2020 Jun 20;4(8):1218-1228. doi: 10.1002/hep4.1535. eCollection 2020 Aug. Hepatol Commun. 2020. PMID: 32766480 Free PMC article.
Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, Torimura T. Shimose S, et al. Among authors: noda y. Cancers (Basel). 2021 Jan 5;13(1):160. doi: 10.3390/cancers13010160. Cancers (Basel). 2021. PMID: 33466496 Free PMC article.
Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound.
Kamachi N, Nakano M, Okamura S, Niizeki T, Iwamoto H, Shimose S, Shirono T, Noda Y, Kuromatsu R, Koga H, Torimura T. Kamachi N, et al. Among authors: noda y. Cancer Rep (Hoboken). 2022 Feb;5(2):e1471. doi: 10.1002/cnr2.1471. Epub 2021 Jun 9. Cancer Rep (Hoboken). 2022. PMID: 34105904 Free PMC article.
The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, Tada F, Rimini M, Tanaka M, Torimura T, Suga H, Ohama H, Burgio V, Niizeki T, Moriyama E, Suzuki H, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: noda y. Hepatol Res. 2023 Feb;53(2):104-115. doi: 10.1111/hepr.13843. Epub 2022 Nov 6. Hepatol Res. 2023. PMID: 36149726
2,067 results